VolitionRX (NYSEAMERICAN:VNRX) Shares Pass Below Fifty Day Moving Average – What’s Next?

VolitionRX Limited (NYSEAMERICAN:VNRX)’s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.87 and traded as low as $0.3362. VolitionRX shares last traded at $0.3499, with a volume of 1,964,367 shares trading hands.

Analyst Ratings Changes

Several brokerages have commented on VNRX. Benchmark reissued a “hold” rating on shares of VolitionRX in a report on Monday, August 17th. Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of VolitionRX in a research report on Thursday, June 18th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, VolitionRX presently has a consensus rating of “Hold” and a consensus price target of $28.00.

VolitionRX Stock Performance

The company has a 50 day moving average of $0.85 and a 200 day moving average of $2.25. The stock has a market capitalization of $4.77 million, a price-to-earnings ratio of -0.09 and a beta of 1.10.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million. On average, equities analysts predict that VolitionRX Limited will post -2.36 EPS for the current fiscal year.

Institutional Trading of VolitionRX

Several large investors have recently bought and sold shares of VNRX. Virtu Financial LLC lifted its stake in VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of VolitionRX in the fourth quarter valued at approximately $28,000. Squarepoint Ops LLC purchased a new position in VolitionRX during the fourth quarter worth approximately $34,000. Armistice Capital LLC boosted its stake in VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.